WashU biotech firm Wugen raises $115M to advance rare cancer drug treatment
Wugen, a St. Louis biotech firm in the clinical stages of developing a drug for a rare form of cancer, has closed a $115 million Series C funding round. The startup, based in the Cortex Innovation District, was created through
Read More...